Germline testing for BRCA1 and BRCA2 mutations may have therapeutic implications since evidence supports poly (ADP-ribose) polymerase inhibitor response in patients with BRCA1- and BRCA2-mutated and metastatic BC.59,60 Olaparib and talazoparib, poly (ADP-ribose) polymerase inhibitors, improve progression-free survival in germline BRCA1- and BRCA2-mutated metastatic BC. The gene discussed is BRCA1; the disease is breast cancer.